Dead languages aren't as unimportant as they seem, because learning Latin, Sanskrit and Ancient Greek will make coding easier ...

Recursion Pharmaceuticals (NASDAQ: RXRX) experienced an 11% increase in stock price on Wednesday after JP Morgan raised its rating, noting the promising potential of its MEK inhibitor program. However ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Want to stay on top of ...

Function Health, a startup that offers lab testing and body scans for early disease detection, scored nearly $300 million in series B funding, boosting its valuation to $2.5 billion. Redpoint Ventures ...

From electronic health records and blood tests to the stream of data from wearable devices, the amount of health information people generate is accelerating rapidly. Yet, many users struggle to ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

Functions are the building blocks of Python programming. They let you organize your code, reduce repetition, and make your programs more readable and reusable. Whether you’re writing small scripts or ...

Functions are the building blocks of Python programs. They let you write reusable code, reduce duplication, and make projects easier to maintain. In this guide, we’ll walk through all the ways you can ...

RXRX stock looks like a deep-value growth bet at just $5 and change. Though the technology is exciting, I’m not rushing into shares just yet. Are you ahead, or behind on retirement? SmartAsset's free ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) shares are volatile on Tuesday following the release of the company’s second-quarter financial results. Here’s what you need to know. RXRX is hovering near ...

The company isn't the only developer of a drug for FAP, a rare genetic disease. A rival just reported that its own FAP treatment is advancing to late-stage testing. This was largely due to news from a ...